Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perspective Therapeutics, Inc. (CATX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Perspective is a radiopharmaceutical development company focused on 212Pb-based theranostic treatments and imaging for cancer, and its filings offer detail on clinical progress, financial condition, and corporate governance.
Recent Form 8-K reports referenced in the input data include announcements of updated corporate presentations, interim clinical results from the Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, and quarterly financial results with business highlights. Other 8-K filings describe executive leadership changes, such as the appointment of a new Chief Financial Officer and amended and restated employment agreements for senior executives, including change-in-control and severance terms.
Through this page, users can review Perspective’s current and historical 8-Ks and, when available, its periodic reports such as Forms 10-K and 10-Q, which typically contain audited or reviewed financial statements, segment information, and risk factor disclosures. These documents help clarify how the company funds its clinical programs, how it accounts for research and development and general and administrative expenses, and how it describes its radiopharmaceutical platform and manufacturing infrastructure enabled by its proprietary 212Pb generator.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major clinical updates, financial trends, and governance changes. Real-time ingestion from EDGAR, along with structured access to items such as executive compensation arrangements and other material contracts, supports deeper analysis of CATX’s regulatory and corporate history.
Perspective Therapeutics, Inc. reported that Chief Medical Officer Markus Puhlmann received a grant of stock options covering 150,000 shares on the grant date of March 2, 2026. The options were approved by the compensation committee as his annual equity award for 2026 and have an exercise price of
The option award vests and becomes exercisable over four years in 48 substantially equal monthly installments, starting one month after the grant date, so long as he continues serving the company on each vesting date. This is a routine equity compensation grant rather than an open‑market share purchase or sale.
Morgan Stanley has filed a Schedule 13G reporting a significant ownership stake in Perspective Therapeutics, Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 4,461,893 shares, representing 6.0% of the company’s common stock.
The firm reports no sole voting or dispositive power, with shared voting power over 3,386,203 shares and shared dispositive power over 3,555,365 shares. Morgan Stanley certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perspective Therapeutics.
Perspective Therapeutics, Inc. received a Schedule 13G from Commodore Capital entities and principals reporting passive ownership of 11,939,753 shares of common stock. This represents 9.9 % of the company’s common shares as of early February 2026.
The position includes 6,336,782 common shares plus 5,602,971 shares issuable upon exercise of a pre-funded warrant that is capped by a 9.99 % beneficial ownership limitation. An additional 995,075 warrant shares are excluded because of this cap. The filers certify the stake is not held to change or influence control of the company.
Perspective Therapeutics, Inc. (CATX) received a Schedule 13G reporting a significant but non-controlling ownership position by TCG Crossover funds and Chen Yu. The filing shows that Chen Yu may be deemed to beneficially own 7,915,567 shares of common stock, equal to 6.9% of the company’s 113,914,078 shares of common stock outstanding.
The holdings are split between TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., which each report beneficial ownership of 3,957,784 and 3,957,783 shares, respectively, or 3.5% of the class each. The reporting parties certify the shares were not acquired to change or influence control of Perspective Therapeutics.
Qatar Investment Authority disclosed a significant passive stake in Perspective Therapeutics Inc. common stock. As of 02/04/2026, it beneficially owned 7,073,308 shares, representing 6.2% of the class, with sole voting and sole dispositive power over all reported shares.
The filing notes that Q Healthcare Holding LLC, a wholly owned subsidiary of Qatar Investment Authority, acquired the securities. Qatar Investment Authority certifies the shares were not acquired to change or influence control of Perspective Therapeutics, indicating a passive investment position.
Perspective Therapeutics, Inc. completed an underwritten equity offering, selling 39,576,088 shares of common stock and issuing pre-funded warrants to purchase 6,598,046 shares, raising approximately $175 million in gross proceeds.
The shares were priced at $3.79 each, and the pre-funded warrants at $3.789 each, reflecting a $0.001 exercise price. The company plans to use net proceeds to advance clinical development of its product candidates, invest in manufacturing facilities, and for working capital and other general corporate purposes, with potential additional use for future acquisitions or licensing opportunities.
Perspective Therapeutics, Inc. is conducting a primary offering of 39,576,088 shares of common stock and pre-funded warrants to purchase 6,598,046 shares of common stock. The shares are priced at $3.79 and the pre-funded warrants at $3.789, with a $0.001 exercise price per warrant share.
The company expects gross proceeds of $174,993,369.81 and net proceeds of approximately $164.0 million after underwriting discounts and expenses. Management plans to use the cash to advance clinical development of its radiopharmaceutical product candidates, invest in manufacturing facilities, and for working capital and general corporate purposes, with potential business development uses.
As of December 31, 2025, Perspective Therapeutics estimates it had approximately $144 million in cash, cash equivalents and short-term investments, and about 74.3 million shares outstanding. The company believes existing cash plus this raise should fund planned milestones and operations into late 2027, though investors will face immediate dilution given the offering price exceeds prior net tangible book value per share.
Perspective Therapeutics, Inc. filed an 8-K to note that it has updated its corporate presentation and posted it on its website. The presentation includes preliminary estimated and projected financial information, including estimated cash, cash equivalents and short-term investments as of December 31, 2025.
The company emphasizes that these figures are unaudited and have not been reviewed or compiled by its independent registered public accounting firm, WithumSmith+Brown, PC, which provides no assurance on the data. Actual results for the year ended December 31, 2025 may differ once closing procedures and final adjustments are completed.
Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation on January 14, 2026. The company is a Delaware corporation whose common stock trades on the NYSE American under the symbol CATX.
The updated corporate presentation is included as Exhibit 99.1 and is incorporated by reference into the Item 8.01 Other Events section. No new financial statements or major transactions are described in this excerpt, which focuses on making the refreshed investor materials publicly available.
Perspective Therapeutics, Inc. filed a current report to let investors know it has issued a new press release describing business updates and strategic priorities. The company states that the press release, dated January 12, 2026, is attached as an exhibit and incorporated by reference, meaning the detailed operational and strategic information is contained in that accompanying document rather than in the body of this report.